Back to top
more

Universal Health Services (UHS)

(Delayed Data from NYSE)

$153.65 USD

153.65
1,047,629

-6.38 (-3.99%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $153.63 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Hospital

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CVS Health (CVS) Gains From Digital Adoption Amid Competition

by Zacks Equity Research

CVS Health (CVS) has been removing barriers to digital adoption and making it easier for customers to access services such as pharmacy refills and advanced scheduling for immunizations online.

GE Healthcare (GEHC), MedQuest Partner to Boost Imaging Field

by Zacks Equity Research

GE Healthcare (GEHC) collaborates with MedQuest to optimize outpatient imaging networks. With AI capabilities from GE Healthcare, MedQuest is likely to provide better solutions in the imaging space.

ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 Device

by Zacks Equity Research

ResMed's (RMD) new AirCurve11 series incorporates myAir and AirView digital health apps to provide maximum comfort and support during therapy.

Are Investors Undervaluing HCA Healthcare (HCA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Cooper Companies (COO), Fulgent Unite to Boost Genetic Testing

by Zacks Equity Research

Cooper Companies (COO) collaborates with Fulgent Genetics to boost newborn genetic screenings. CBR by Cooper Surgical is likely to provide a variety of genetic testing options to its families.

Kaibalya Pravo Dey headshot

Analyzing 3 Healthcare Stocks Poised for Q4 Earnings Beat

by Kaibalya Pravo Dey

Rising patient volumes, admissions, health awareness and technological advancements in the Q4 are likely to have benefited healthcare players like Universal Health (UHS), Alignment Healthcare (ALHC) and Agiliti (AGTI).

Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Fresenius Medical (FMS) Gets FDA Nod for New Hemodialysis System

by Zacks Equity Research

Fresenius Medical (FMS) receives an FDA nod for its new 5008X Hemodialysis System that aims to provide better dialysis therapy for kidney patients in the United States.

DexCom (DXCM) Beats on Q4 Earnings, Strong CGM Demand Continues

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

Baxter's (BAX) Q4 Earnings Top, Sales Rise on Strong Demand

by Zacks Equity Research

Baxter (BAX) reports better-than-expected fourth-quarter earnings and sales. BAX's fourth-quarter and full-year results reflect solid demand for a range of its medically essential products.

Here's Why You Should Invest in Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.

DexCom (DXCM) Launches One+ Real-time CGM System in Europe

by Zacks Equity Research

DexCom (DXCM) unveils its new CGM system, Dexcom ONE+, which is set to provide easy and effective care to diabetic patients.

McKesson (MCK) Beats on Q3 Earnings, Raises FY24 EPS View

by Zacks Equity Research

McKesson's (MCK) third-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.

Microbot Medical (MBOT) Files IDE to Start Human Clinical Study

by Zacks Equity Research

Microbot Medical (MBOT) files an IDE with the FDA, approval of which will enable the company to proceed with its human clinical study in the United States.

Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings

by Zacks Equity Research

Catalent (CTLT) inks a merger agreement with Novo Holdings, under which the latter will acquire Catalent for $16.5 billion.

Hologic (HOLX) Introduces Genius Digital Diagnostics System

by Zacks Equity Research

Hologic's (HOLX) Genius Digital Diagnostics System will assist laboratories and healthcare providers with the information needed to make more timely and successful treatment decisions for patients.

Philips (PHG) Receives FDA Class 1 Recall for BrightView SPECT

by Zacks Equity Research

Philips (PHG) receives an FDA Class 1 recall for BrightView imaging systems.

PacBio's (PACB) New Kits to Boost Its Revio Sequencing System

by Zacks Equity Research

PacBio's (PACB) new library preparation kits are likely to boost Revio's long-read sequencing systems by reducing cost and workflow time.

InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS

by Zacks Equity Research

InspireMD's (NSPR) CE Mark Recertification under MDR is likely to help the company boost the CGuard EPS for carotid artery revascularization care along with advancing with new products.

CONMED (CNMD) Misses on Q4 Earnings, Beats Revenue Estimates

by Zacks Equity Research

CONMED's (CNMD) adjusted fourth-quarter earnings misses while sales beat estimates on the back of strong growth in the United States and international markets. Gross margin improves with a rise in sales.

Philips' (PHG) New Innovation to Enhance Cardiovascular Imaging

by Zacks Equity Research

Philips' (PHG) latest X11-4t Mini 3D TEE transducer is likely to have an edge over the traditional 3D TEE in terms of catering to a broader range of patients and improved overall comfort.

LabCorp (LH) Unveils Test for Preeclampsia in Pregnant Women

by Zacks Equity Research

LabCorp (LH) test System, which is available through clinicians, is the first FDA-cleared biomarker test to aid in the risk assessment of progression to severe preeclampsia.

Why Universal Health Services (UHS) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Universal Health Services (UHS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Revvity (RVTY) Q4 Earnings Top, EPS View Above Expectation

by Zacks Equity Research

Revvity's (RVTY) fourth-quarter results showcase the decline in segmental revenues. However, the company's earnings and revenues beat their respective estimates.

Cardinal Health (CAH) Buys Specialty Networks to Boost Workflow

by Zacks Equity Research

Cardinal Health (CAH) acquires Specialty Network to technologically strengthen its specialty therapeutic areas. The acquisition also supports the company's ongoing Navista Network.